Geron Earnings Call Highlights RYTELO-Driven Momentum

Geron Corporation ((GERN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Geron’s latest earnings call painted a broadly upbeat picture, with strong revenue growth, rising demand and tighter cost controls offsetting pressure from higher gross‑to‑net discounts and a notable cash drawdown. Management emphasized that clinical progress and commercial momentum for RYTELO keep the company on track for its 2026 targets, despite unresolved questions around European pricing and future trial outcomes.

Strong top-line growth and on-track guidance

RYTELO delivered net revenue of $51.8 million in the first quarter of 2026, a 31% increase year over year and 8% sequentially, underscoring robust uptake in lower‑risk MDS. Executives reiterated full‑year 2026 net revenue guidance of $220 million to $240 million, signaling confidence that current trends can sustain through the year.

Commercial demand and account expansion

Underlying demand grew roughly 6% quarter over quarter, while prescribing accounts have expanded about 12% since launch to approximately 1,450. The mix of first‑ and second‑line patient starts improved on a rolling 12‑month basis to about 33%, up from around 30%, suggesting deeper penetration earlier in the treatment journey.

Clinical progress and scientific validation

The Phase III IMpactMF trial is now fully enrolled, with an interim analysis slated for the second half of 2026 and a final readout planned in the back half of 2028. Recent publication in Blood Cancer Journal, anticipated data at ASH 2025 and inclusion in the NCCN chemotherapy order template collectively reinforce imetelstat’s differentiation and support its positioning in lower‑risk MDS.

Financial discipline and operating expense reductions

Geron reported total operating expenses excluding cost of goods sold of $50.4 million in the quarter, down from $55.1 million a year earlier, roughly a 9% reduction. SG&A fell to $35.4 million from $40.0 million, while R&D held steady at about $15 million, reflecting workforce reductions and tighter spending without sacrificing key commercial initiatives.

Strategic commercial investments and market engagement

The company is stepping up both in‑person and digital engagement, leaning into targeted channels such as digital non‑personal promotion and third‑party education. Management is also backing investigator‑sponsored trials and real‑world evidence programs to build confidence among U.S. hematologists and further embed RYTELO in clinical practice.

Progress on ex-U.S. strategy and leadership additions

Outside the United States, Geron is advancing health technology assessment work, pricing research and dialogue with European experts as it shapes its launch approach. To support this next phase, the company has bolstered its leadership bench by appointing a new Chief Legal Officer and adding two directors to its board.

Widening gross-to-net reductions

Gross‑to‑net reductions climbed to 21% in the first quarter from 13% a year earlier, driven by broader 340B utilization and expanded group purchasing organization contracting. Management now expects gross‑to‑net to stay in the low‑ to mid‑20% range through 2026, which will temper the conversion of strong demand into realized net revenue.

Cash balance decline in the quarter

Cash, cash equivalents, restricted cash and marketable securities fell to about $341 million as of March 31, 2026, down from $401 million at year‑end, roughly a 15% decline. The reduction reflected the timing of annual bonus payments, severance tied to the December 2025 restructuring and continued CMC investments aimed at fortifying the supply chain.

Uncertainty around IMpactMF interim outcome

While the IMpactMF trial’s enrollment milestone removes an execution risk, the company remains blinded to outcomes ahead of the interim analysis planned for the second half of 2026. Management acknowledged that a negative or neutral interim read could dampen enthusiasm for the broader imetelstat platform and potentially limit read‑through to adoption in MDS.

Europe commercialization and pricing uncertainty

Geron’s European playbook is still taking shape, with pricing, partnership options and go‑to‑market design all under active evaluation. The company has ruled out a large stand‑alone infrastructure build, but without a confirmed model, investors face continued uncertainty around the timing, scale and profitability of ex‑U.S. revenue.

Near-term cash headwinds from investments

Beyond one‑time items such as bonuses and severance, Geron is committing capital to ongoing CMC and supply‑chain projects that it views as critical to long‑term resilience. These investments contributed to the first‑quarter cash outflow and could weigh on near‑term free cash flow even as management maintains confidence in meeting its 2026 targets.

Forward-looking guidance and outlook

Management reaffirmed guidance for 2026, calling for RYTELO net revenue between $220 million and $240 million and total operating expenses of $230 million to $240 million, supported by first‑quarter revenue of $51.8 million and a 9% year‑over‑year opex decline. The company flagged that a greater portion of growth should come in the back half of 2026, as IMpactMF interim data and initial real‑world evidence begin to shape physician behavior.

Geron’s earnings call underscored a company balancing near‑term financial pressures with long‑term value creation through disciplined spending and clinically driven growth. For investors, the story hinges on whether RYTELO’s U.S. momentum can offset rising discounts and cash burn, while upcoming trial readouts and European decisions define the next leg of the growth narrative.